Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.
Bimmugen [Recombinant adsorbed hepatitis B vaccine (yeast-derived)] is Kaketsuken’s monovalent vaccine that protects infants against acute and chronic infections caused by all known strains of HBV. In 1988, Bimmugen became the first HBV vaccine available in Japan. The antigen contained in Bimmugen, purified recombinant HBsAg, is obtained by culturing S. cerevisiae cells that have been genetically engineered to express the viral protein. All dosages and formulations of Bimmugen are administered by intramuscular injection.
Overview of Hepatitis B disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Bimmugen including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Bimmugen for Japan from 2012 to 2022.
Sales information covered for Japan
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Bimmugen performance
Obtain sales forecast for Bimmugen from 2012-2022 in Japan.